Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer

Yildiz, Ramazan; Benekli, Mustafa; ÖZKAN, METİN; Alkis, Necati; Berk, Veli; Kaplan, Mehmet; Ciltas, Aydin; Karaca, Halit; Durnali, Ayse; Coskun, Ugur; Dikilitas, Mustafa; Sevinc, Alper; Dane, Faysal; Yetisyigit, Tarkan; Dogu, Gamze; Buyukberber, Suleyman

doi:10.1007/s00432-012-1264-5

Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer

Yildiz R., Benekli M., ÖZKAN M., Alkis N., Berk V., Kaplan M. A., ...Daha Fazla

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.138, sa.11, ss.1845-1852, 2012 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 138 Sayı: 11
Basım Tarihi: 2012
Doi Numarası: 10.1007/s00432-012-1264-5
Dergi Adı: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1845-1852
Erciyes Üniversitesi Adresli: Evet

Özet

The efficacy and tolerability of bevacizumab every 2 or 4 weeks using the same dosage in combination with biweekly FOLFIRI were retrospectively evaluated in metastatic colorectal cancer (mCRC) patients in the first-line and second-line therapy.